Return to CG181 Overview

Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]

Measuring the use of this guidance

Recommendation: 1.2.7

Advise people at high risk of or with CVD to do the following every week: at least 150 minutes of moderate intensity aerobic activity or 75 minutes of vigorous intensity aerobic activity or a mix of moderate and vigorous aerobic activity in line with national guidance for the general population (see Physical activity guidelines for adults at NHS Choices)

What was measured: Public Health Outcomes Framework indicator 2.13: Proportion of over 16s doing at least 150 “equivalent” minutes of at least moderate intensity physical activity per week in bouts of 10 minutes or more in the previous 28 days.
Data collection end: December 2012
56%
Data collection end: December 2013
56%
Data collection end: December 2014
57%
Area covered: England
Source: Sport England - Active people survey


Recommendation: 1.3.18

Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10‑year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.

What was measured: CVD-PP001: In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins.
Data collection end: July 2015
67.7%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.

What was measured: In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins.
Data collection end: July 2015
67.7%
Area covered: England
Source: Health and Social Care Information Centre. Quality Outcomes Framework.

What was measured: Proportion of patients in Wales between May 2008 and December 2014 prescribed a statin for primary prevention of CVD who were prescribed atorvastatin.
Data collection end: December 2014
8%
Area covered: Wales
Source: Protty Majd B, Lacey Arron, Hayes Jamie, and Freeman Phillip. (2016). Statins for primary prevention in practice: clinical use in Wales and the NICE guideline effect. British journal of clinical pharmacology, 82(3), pp.892-4.


Recommendation: 1.3.27

Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD[7]

What was measured: Proportion of people with known CKD who were prescribed statins
Data collection end: June 2016
68.8%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit National Report (Part 1)


Recommendation: 1.7.8

If not already measured, check the haemoglobin level in people with a GFR of less than 45 ml/min/1.73 m2 (GFR category G3b, G4 or G5) to identify anaemia (haemoglobin less than 110 g/litre [11.0 g/dl], see Anaemia management in people with chronic kidney disease [NICE guideline CG114]). Determine the subsequent frequency of testing by the measured value and the clinical circumstances. [2008]

What was measured: Proportion of people who had an eGFR<45ml/min who were recorded as having a haemoglobin blood test to screen for renal anaemia
Data collection end: June 2016
73.9%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit National Report (Part 1)



 Return to CG181 Overview